Information Provided By: 
Fly News Breaks for March 12, 2018
SRPT
Mar 12, 2018 | 11:06 EDT
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Sarepta Therapeutics to $92 after the company announced plans to initiate a rolling new drug application submission for golodirsen. The analyst models U.S. commercial launch during Q3 of 2019, or about two quarters behind his original projections. Positive FDA meeting minutes on golodirsen imply a higher probability of approval, Chattopadhyay tells investors in a research note partially titled "Exondys 51 Was Not a Onetime Hail Mary." He keeps a Buy rating on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
